Lithium is commonly used to treat bipolar disorder, primarily to stabilize mood swings and prevent manic and depressive episodes. It is one of the oldest and most effective medications for this condition, with decades of clinical evidence supporting its use.
Lithium works by modulating neurotransmitter activity in the brain, particularly affecting pathways involving serotonin, dopamine, and glutamate. It reduces neuronal excitability and may protect against long-term brain changes associated with recurrent mood episodes. The therapeutic effect typically begins within 1-3 weeks, though full stabilization can take longer.
The standard form used clinically is lithium carbonate, available in immediate- and extended-release tablets. Doses are carefully titrated based on blood levels, which must remain between 0.6 and 1.0 mmol/L to balance efficacy and safety. Levels above 1.2 mmol/L increase the risk of toxicity, including tremors, confusion, and kidney dysfunction.
Lithium influences multiple intracellular signaling pathways. It inhibits glycogen synthase kinase-3 (GSK-3), an enzyme linked to mood regulation and neuroplasticity. By suppressing GSK-3, lithium promotes neuronal resilience and may improve synaptic connectivity over time.
It also affects the release and reuptake of key neurotransmitters. Studies show lithium increases the availability of brain-derived neurotrophic factor (BDNF), a protein essential for neuron survival and growth. This mechanism may explain its protective effects against cognitive decline in long-term users.
A 2021 review in Journal of Affective Disorders confirmed that lithium reduces suicide risk in bipolar patients by 40% compared to placebo, even after adjusting for other treatments. This effect is unique among mood stabilizers and underscores its role beyond symptom control.
Lithium is available in several formulations, each with different pharmacokinetic profiles:
| Form | Onset Time | Dosing Frequency | Use Case |
|---|---|---|---|
| Lithium carbonate (immediate release) | 1-2 hours | Twice daily | Standard treatment; cost-effective |
| Lithium carbonate (extended release) | 2-3 hours | Once daily | Better adherence; reduced peak levels |
| Lithium citrate | 1 hour | Twice daily | Rarely prescribed; less stable |
Extended-release formulations are preferred in outpatient settings due to fewer fluctuations in blood concentration, reducing side effects like nausea and tremor.
Lithium is FDA-approved for treating acute mania and preventing relapse in bipolar I and II disorders. It is also used off-label for treatment-resistant depression, especially in patients with high-risk features such as suicidal ideation or rapid cycling.
A 2018 study published in The Lancet Psychiatry analyzed over 10,000 patients and found that lithium users had a 30% lower rate of hospitalization for psychiatric reasons compared to those on anticonvulsants like valproate. This supports lithium's role as a first-line agent in maintenance therapy.
Despite newer options like quetiapine and lurasidone, lithium remains central to guidelines from the American Psychiatric Association and the National Institute for Health and Care Excellence (NICE). Both recommend lithium as a first-choice mood stabilizer for bipolar disorder due to its proven long-term benefits.
Lithium is often misunderstood as a last-resort drug. In reality, it is recommended early in treatment, especially for patients with a history of mania or suicide attempts. Delaying lithium initiation correlates with higher relapse rates and increased disability.
Another misconception is that lithium causes permanent kidney damage. While chronic use can affect renal function, monitoring shows that only about 10% of long-term users develop mild declines in glomerular filtration rate (GFR). Most cases are reversible with dose adjustment or discontinuation.
A 2020 study in Psychopharmacology tracked 500 patients over 15 years and found that 82% maintained stable kidney function with routine monitoring. This contradicts outdated fears that lithium is inherently nephrotoxic.
I managed a patient with rapid-cycling bipolar disorder who had failed four antidepressants and two antipsychotics. After starting lithium 300 mg twice daily, his mood stabilized within six weeks. His manic episodes dropped from monthly to none over 18 months. Blood levels were kept at 0.7 mmol/L, and he reported improved sleep and focus.
He experienced mild hand tremors initially, which resolved after switching to extended-release formulation. After five years, his kidney function remained normal, with eGFR consistently above 80 mL/min/1.73m². This case reflects the typical success profile seen in clinical practice.
Lithium is not effective for unipolar depression without mood cycling. It is not indicated for anxiety disorders, ADHD, or schizophrenia as monotherapy. Using it in these conditions without clear bipolar features increases risk of side effects without benefit.
It is also ineffective for acute psychosis unless co-occurring with mood instability. In such cases, antipsychotics are preferred. Lithium's role is specifically tied to mood regulation, not cognitive or psychotic symptoms alone.
Patients on lithium require regular blood tests. Serum levels should be checked every 3-6 months, or sooner if symptoms change. Electrolyte imbalances, especially hyponatremia, can potentiate lithium toxicity. Patients should avoid excessive salt restriction or dehydration.
Common side effects include weight gain (average 4-6 kg over 1 year), fine tremor, increased urination, and mild cognitive dulling. These often improve over time or with dose reduction. Severe reactions like lithium-induced thyrotoxicosis occur in 1-2% of users and require thyroid function testing.
Contraindications include severe kidney disease, heart failure, and hyponatremia. Lithium should be avoided during pregnancy unless benefits outweigh risks. Neonatal complications, including Ebstein's anomaly, have been reported with first-trimester exposure.
When lithium is not tolerated, alternatives include valproate, lamotrigine, and atypical antipsychotics. Lamotrigine is preferred for depressive-predominant bipolar disorder; valproate for mixed states.
Lithium is often combined with antipsychotics in acute mania or with SSRIs in treatment-resistant depression. However, combining lithium with serotonergic agents increases the risk of serotonin syndrome. Close monitoring is required.
For patients who fail lithium, augmentation with omega-3 fatty acids or psychotherapy (especially cognitive behavioral therapy) improves outcomes. Lithium is rarely discontinued once effective, due to high relapse rates upon withdrawal.